Company
Headquarters: Adelaide, SA, Australia
CEO: Mr. Brenton John Barnes
A$11.3 Million
AUD as of Jan. 1, 2024
US$7.7 Million
Company | Market Cap (USD) |
---|---|
Abbott | $192.67 B |
Stryker Corporation | $113.24 B |
Medtronic | $111.60 B |
Boston Scientific Corporation | $85.22 B |
Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $49.33 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
LBT Innovations Limited engages in the research, development, and commercialization of technologies for the healthcare and laboratory supply markets in Australia and Switzerland. The company offers MicroStreak, an automated culture-plate streaking and inoculation system; and Automated Plate Assessment System, a platform technology that automates culture-plate screening and interpretation. It also develops Automated Gram Strain Assessment for the automated interpretation of gram stain image analysis; WoundVue, a technology that uses artificial intelligence to assist clinicians in the assessment and care of chronic wounds; and devices that can detect biofilms in the presence of mammalian tissue. The company was incorporated in 2004 and is headquartered in Adelaide, Australia.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
LBT Innovations Limited has the following listings and related stock indices.
Stock: ASX: LBT wb_incandescent